Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2018

View Archived Issues

FDA grants orphan drug designation to Lin's LBS-007

Mirati Therapeutics updates progress of key programs

Ono applies for manufacturing and marketing approval of encorafenib and binimetinib in Japan

ADC Therapeutics terminates its ADCT-502 program in HER2-expressing solid tumors

First patient dosed in phase IIb study of chikungunya VLP vaccine

FDA grants fast track designation to SYNB-1618

STRIVE trial results show promise for AVXS-101 in spinal muscular atrophy type 1 patients

FDA accepts for review sBLA for Fluzone Quadrivalent 0.5 mL for younger children

AbbVie submits BLA to the FDA for risankizumab in moderate to severe plaque psoriasis

Novel glucose transporter inhibitor SRI-37919 reduces glioblastoma cell growth

Chugai reviews highlights of first quarter 2018

Long-term exposure to ZYN-002 improves focal seizure frequency in epilepsy patients

Entasis Therapeutics and Zai Lab enter strategic development collaboration for ETX-2514

Phase IIb/III rheumatoid arthritis study of upadacitinib in Japanese patients meets primary endpoint

European Commission approves new dosing schedules for Opdivo

Sumitomo Dainippon Pharma, MMV enter joint research agreement

Phase III results presented for solriamfetol on excessive sleep in narcolepsy patients

Durect initiates patient dosing in phase IIa study of DUR-928 in alcoholic hepatitis

Maxinovel Pharmaceuticals presents the discovery of small-molecule PD-1/PD-L1 inhibitors

FDA grants fast track designation for ORP-101

Zealand holds end-of-phase II meeting with FDA on glepaglutide for short bowel syndrome

AveXis initiates phase III SPRINT trial of AVXS-101 in presymptomatic patients with SMA

Interim phase II results encouraging for tropifexor in primary biliary cirrhosis

Phase I/II results for DS-5141 in patients with DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...